FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that Sheldon Lin, M.D., one of the U.S. clinical investigators, will review follow-up results from ongoing U.S. and Canadian clinical trials evaluating GEM OS1 Bone Graft in foot and ankle fusion indications. Dr. Lin’s presentation is scheduled for July 13, 2007 at 9:25 a.m. EDT at the American Orthopedic Foot and Ankle Society Meeting (AOFAS) which is being held in Toronto, Canada. The Company will host a conference call to discuss the study’s findings at 12:00 p.m. EDT the same day. Members of management and Dr. Lin will participate in the call which will include a brief Q&A session.
